alzheon, Author at Alzheon | Preserving Future Memories - Page 3 of 20

About alzheon

This author has not yet filled in any details.
So far alzheon has created 200 blog entries.

5 Dec, 2023

Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer and Strengthens Commercial Organization with New Executive Appointments to Lead Planned U.S. Commercial Launch of Oral ALZ-801/Valiltramiprosate in 2025

alzheon2024-08-05T19:57:04-04:00December 5th, 2023|

31 Oct, 2023

Alzheon CEO Dr. Martin Tolar to Discuss Positive Results from Phase 2 Biomarker Study and Upcoming Readout from Pivotal APOLLOE4 Phase 3 Study Evaluating Oral ALZ-801/Valiltramiprosate at Truist Securities BioPharma Symposium

alzheon2024-08-05T19:28:01-04:00October 31st, 2023|

17 Oct, 2023

Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer’s Disease Conference

alzheon2024-08-12T09:52:46-04:00October 17th, 2023|

26 Sep, 2023

Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer’s Disease Day, and BIO Investor Forum

alzheon2024-08-12T10:07:38-04:00September 26th, 2023|

22 Sep, 2023

ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s

alzheon2023-10-02T11:49:22-04:00September 22nd, 2023|

18 Sep, 2023

Alzheimer Agent ALZ-801 Improves Cognition, Reduces Relevant Biomarker Levels in 2-Year Analysis

alzheon2023-09-21T10:37:23-04:00September 18th, 2023|

13 Sep, 2023

Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

alzheon2024-08-05T19:59:29-04:00September 13th, 2023|

16 Jul, 2023

AAIC: A Pill to Slow Down Alzheimer’s Is About Two Years Away

alzheon2023-07-18T10:41:12-04:00July 16th, 2023|

13 Jul, 2023

Venture Capitalists Fund New Generation of Alzheimer’s Drugs

alzheon2024-06-06T17:58:07-04:00July 13th, 2023|Tags: WSJ|

11 Jul, 2023

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at Alzheimer’s Association International Conference in Amsterdam

alzheon2024-08-12T09:43:10-04:00July 11th, 2023|